greeksoup/ stock research
Stock research / United States / AZN / Year to 31 December 2019

AstraZeneca PLC (AZN) annual results, year to 31 December 2019: revenue USD 24,384 million, from the 20-F

AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2019 it reported revenue of USD 24,384 million, up 10.4% on the year before. Its profit attributable to shareholders was USD 1,335 million, down 38.1%, and diluted earnings per share USD 1.03.

Revenue
USD 24,384 million
+10.4% on the year
FY2015FY2019
Operating margin
12.0%
15.3% a year earlier
FY2015FY2019
Net income
USD 1,335 million
-38.1% on the year
FY2015FY2019
Diluted EPS
USD 1.03
-39.4% on the year
FY2015FY2019

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2018Dec 2019
Revenue22,09024,384
Cost of sales4,9364,921
Gross profit17,15419,463
Research and development5,9326,059
Selling, general and administrative10,03111,682
Operating profit3,3872,924
Finance costs1,4191,432
Profit before tax1,9931,548
Income tax-57.0321
Profit for the year2,0501,227
Profit attributable to shareholders2,1551,335
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2018Dec 2019
Diluted EPS1.701.03
Basic EPS1.701.03
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2018Dec 2019
Cash from operations2,6182,969
Purchase of property, plant and equipment1,043979
Free cash flow1,5751,990
Cash from investing963-657
Cash from financing-2,044-1,765
Dividends paid3,4843,592
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2018Dec 2019
Funded by
Equity attributable to shareholders12,46813,127
Non-controlling interests1,5761,469
Borrowings, as filed19,11317,552
Lease liabilitiesn/a675
Other liabilities27,49428,554
Total equity and liabilities60,65161,377
Owned
Property, plant and equipment7,4217,688
Goodwill11,70711,668
Other intangible assets21,95920,833
Cash and cash equivalents4,8315,369
Trade and other receivables5,5745,761
Inventories2,8903,193
Other assets6,2696,865
Total assets60,65161,377
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2018Dec 2019
Gross margin77.7%79.8%
Operating margin15.3%12.0%
Net margin9.8%5.5%
Free cash flow margin7.1%8.2%
Return on year-end equity17.3%10.2%
Effective tax rate-2.9%20.7%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2019, filed 22 February 2022: the filing. The figures are in US dollars as filed.